No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
0.9% sodium chloride |
Sodium chloride |
D02056 |
- |
- |
3件: 6, 14, 51 |
2 |
10% intravenous immunoglobulin (ivig) |
Immune globulin human |
- |
- |
- |
1件: 14 |
3 |
Albumin (human) 25%, united states pharmacopeia (usp) |
- |
- |
- |
- |
2件: 13, 14 |
4 |
Anti-c5 antibody |
- |
- |
- |
- |
4件: 11, 14, 62, 109 |
5 |
Anti-thymocyte globulin |
- |
- |
- |
- |
18件: 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
6 |
Carmustine |
Carmustine |
D00254 |
- |
- |
5件: 11, 13, 14, 28, 60 |
7 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
8 |
Clairyg 50 mg/ml |
- |
- |
- |
- |
1件: 14 |
9 |
Clairyg 50mg/ml |
- |
- |
- |
- |
1件: 14 |
10 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
11 |
Cyclosporin |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
16件: 14, 38, 39, 49, 53, 56, 60, 62, 63, 97, 113, 164, 222, 223, 274, 326 |
12 |
Cyclosporin a |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
11件: 14, 38, 39, 49, 53, 56, 60, 62, 63, 113, 164 |
13 |
Cyclosporine |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
33件: 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
14 |
Cytarabine |
Cytarabine |
D00168, D03046, D03637 |
- |
- |
6件: 11, 13, 14, 25, 49, 60 |
15 |
Eculizumab |
Eculizumab |
D03940 |
1件: C5 |
7件: Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
7件: 11, 13, 14, 62, 109, 222, 223 |
16 |
Etoposide |
Etoposide |
D00125, D04107 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
17 |
Fibrinogen |
Fibrinogen human |
- |
- |
- |
3件: 14, 65, 288 |
18 |
Fibrinogen concentrate |
Fibrinogen human |
- |
- |
- |
1件: 14 |
19 |
Fingolimod |
Fingolimod |
D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
3件: 13, 14, 156 |
20 |
Freeze-dried sulfonated human normal immunoglobulin (ggs) |
Immune globulin human |
- |
- |
- |
3件: 14, 43, 45 |
21 |
Fty720 |
- |
- |
- |
- |
2件: 13, 14 |
22 |
Gammanorm |
- |
- |
- |
- |
2件: 14, 65 |
23 |
H.p. acthar® gel |
- |
- |
- |
- |
1件: 14 |
24 |
Hematopoietic stem cell transplantation |
- |
- |
- |
- |
12件: 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285 |
25 |
Hizentra |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
26 |
Hizentra® |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
27 |
Human immunoglobulin g |
Immune globulin human |
- |
- |
- |
3件: 14, 50, 63 |
28 |
Human normal 10% immunoglobulin for intravenous administration |
- |
- |
- |
- |
1件: 14 |
29 |
Human normal immunoglobulin |
Immune globulin human |
- |
- |
- |
8件: 11, 13, 14, 43, 45, 50, 63, 65 |
30 |
Human normal immunoglobulin (iv) |
Immune globulin human |
- |
- |
- |
4件: 11, 14, 63, 65 |
31 |
Human normal immunoglobulin (scig) |
Immune globulin human |
- |
- |
- |
1件: 14 |
32 |
Human normal immunoglobulin for intravenous administration |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
33 |
Human normal immunoglobulin g (igg > 98% purity) |
Immune globulin human |
- |
- |
- |
2件: 14, 63 |
34 |
Hyqvia |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
35 |
Hyqvia 100 mg/ml solution for infusion for subcutaneous use |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
36 |
I10e |
- |
- |
- |
- |
3件: 14, 63, 65 |
37 |
I10e (human normal immunoglobulin for intravenous administration 100mg/ml) |
Immune globulin human |
- |
- |
- |
1件: 14 |
38 |
Igiv |
- |
- |
- |
- |
1件: 14 |
39 |
Igiv, 10% |
- |
- |
- |
- |
2件: 14, 65 |
40 |
Igpro10 |
- |
- |
- |
- |
3件: 14, 51, 65 |
41 |
Igpro20 |
- |
- |
- |
- |
3件: 14, 51, 65 |
42 |
Igpro20 (high dose) |
- |
- |
- |
- |
1件: 14 |
43 |
Igpro20 (low dose) |
- |
- |
- |
- |
1件: 14 |
44 |
Igvena*fl 200ml 10g+set |
- |
- |
- |
- |
1件: 14 |
45 |
Immune globulin |
- |
- |
- |
- |
3件: 11, 13, 14 |
46 |
Immune globulin 10% intravenous solution |
- |
- |
- |
- |
1件: 14 |
47 |
Immune globulin intravenous |
Immune globulin human |
- |
- |
- |
3件: 14, 63, 65 |
48 |
Immune globulin intravenous (human), 10% |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
49 |
Immune globulin iv (human), 10% caprylate/chromatography purified |
- |
- |
- |
- |
1件: 14 |
50 |
Immune globulin subcutaneous |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
51 |
Immune globulin subcutaneous (human) |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
52 |
Immunoglobulin |
- |
- |
- |
- |
2件: 13, 14 |
53 |
Immunoglobulin g |
Immune globulin human |
- |
- |
- |
7件: 11, 13, 14, 49, 50, 63, 65 |
54 |
Immunoglobulin perfusion |
- |
- |
- |
- |
1件: 14 |
55 |
Immunoglobuline g |
- |
- |
- |
- |
1件: 14 |
56 |
Immunoglobulins |
- |
- |
- |
- |
1件: 14 |
57 |
Immunoglobulins, normal human, for intravascular adm. |
- |
- |
- |
- |
2件: 14, 15 |
58 |
Interferon beta |
Human interferon beta |
- |
- |
- |
6件: 13, 14, 20, 26, 96, 97 |
59 |
Interferon beta-1a |
Human interferon beta |
- |
- |
- |
5件: 13, 14, 26, 96, 97 |
60 |
Intravenous gammaglobulin |
- |
- |
- |
- |
1件: 14 |
61 |
Intravenous immunoglobulin |
Immune globulin human |
- |
- |
- |
16件: 2, 11, 14, 17, 18, 35, 38, 39, 49, 51, 63, 65, 85, 164, 296, 309 |
62 |
Intravenous immunoglobulin (ivig) |
Immune globulin human |
- |
- |
- |
4件: 14, 17, 164, 296 |
63 |
Iqymune |
- |
- |
- |
- |
1件: 14 |
64 |
Ivig |
Immune globulin human |
- |
- |
- |
12件: 11, 13, 14, 17, 18, 50, 51, 63, 65, 85, 164, 296 |
65 |
Kiovig |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
66 |
Kiovig 100 mg/ml solution for infusion |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |
67 |
Kiovig® (human normal immunoglobulin for intravenous administration 100mg/ml) |
Immune globulin human |
- |
- |
- |
1件: 14 |
68 |
Lipoic acid |
Lipoic acid |
D00048, D00086 |
- |
- |
5件: 2, 5, 13, 14, 20 |
69 |
Md1003 |
- |
- |
- |
- |
5件: 2, 10, 13, 14, 20 |
70 |
Melphalan |
Melphalan |
D00369 |
- |
- |
14件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285 |
71 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
72 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
73 |
Newgam |
- |
- |
- |
- |
3件: 14, 63, 65 |
74 |
Newgam 10% |
- |
- |
- |
- |
1件: 14 |
75 |
Npb-01 |
- |
- |
- |
- |
3件: 13, 14, 162 |
76 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
77 |
Panzyga |
Immune globulin human |
- |
- |
- |
1件: 14 |
78 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
79 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
80 |
Privigen |
Immune globulin human |
- |
- |
- |
4件: 11, 14, 51, 65 |
81 |
Privigen® |
Immune globulin human |
- |
- |
- |
2件: 14, 63 |
82 |
Rhuph20 |
- |
- |
- |
- |
2件: 13, 14 |
83 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
84 |
Rozanolixizumab |
Rozanolixizumab |
- |
- |
- |
2件: 11, 14 |
85 |
Same |
Ademetionine |
D07128 |
- |
- |
15件: 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
86 |
Sodium chloride |
Sodium chloride |
D02056 |
- |
- |
13件: 6, 11, 13, 14, 34, 46, 51, 168, 193, 227, 228, 288, 299 |
87 |
Soliris |
Eculizumab |
D03940 |
1件: C5 |
7件: Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
7件: 11, 13, 14, 62, 109, 222, 223 |
88 |
Standard of care |
- |
- |
- |
- |
8件: 6, 13, 14, 49, 51, 64, 79, 85 |
89 |
Subcuvia |
- |
- |
- |
- |
3件: 14, 49, 65 |
90 |
Tegeline 50mg/ml |
- |
- |
- |
- |
1件: 14 |
91 |
Vivaglobin |
Immune globulin human |
- |
- |
- |
2件: 14, 65 |